Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
about
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancerActive surveillance for prostate cancer: current evidence and contemporary state of practiceIntegration of multiparametric MRI into active surveillance of prostate cancer.Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Expectant management for men with early stage prostate cancer.Active Surveillance for Intermediate Risk Prostate Cancer.Role of prostate magnetic resonance imaging in active surveillance.Evaluating the Role of mpMRI in Prostate Cancer Assessment.Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.Current Management Strategy for Active Surveillance in Prostate Cancer.Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.Active Surveillance in Younger Men With Prostate Cancer.In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillanceSociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management.Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.Can nomograms improve our ability to select candidates for active surveillance for prostate cancer?Management of prostate cancer: NYU Case of the Month, July 2017.Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes.Expanded criteria for active surveillance in prostate cancer: a review of the current data.Rethinking active surveillance for prostate cancer in African American men
P2860
Q26795625-4665B708-DE54-43E7-9A6F-D1024667BCABQ28066534-D3B03B28-747D-42C1-9FE2-FAFBD886B557Q30249514-08D202CF-FDB5-4172-9280-9EE5D0FB58B7Q30393322-5CC1DD3F-50D7-4743-9EBF-541EFE78113BQ36892392-53C4A4CC-3942-495B-A572-499378279648Q37029385-97AC91F1-EFF2-4583-B729-43DBE96C9FCBQ38469754-126C8D21-DF94-4E57-A5AB-85D36CDA057CQ38627996-5AD0CA4E-74CA-4AA9-A928-F679968F8370Q38671172-30D6C2A6-1613-43EE-B790-DE68E2B1F32AQ38675322-AF7A2F9A-9FD2-446B-888B-EBA5EC068401Q38823187-BCCC289F-4BC8-4053-9728-B535A159DD53Q38950908-7DBBEBB5-A23A-48C0-ABD3-3B21DE473741Q39356200-6D9DFF00-72B3-4BF1-BBB8-E198A4E25E09Q40271880-CB463F25-A032-46B4-915A-6401D767365DQ40561072-560ABBE5-2911-4238-89BB-35F38942DE94Q41662619-A82417C3-61E5-4A63-A6B2-87CBA5D09E7EQ44607269-6A970877-C2AE-4886-83F5-8C3B75C28DE4Q46732425-0EE66FED-2010-47EF-8A57-97FE6A3E4F36Q46883564-72D751C3-E311-4D1D-B3A2-1EE2BBB11B0EQ50184941-2B9ABC11-6309-4323-8A33-44B1571D4329Q50227153-0284BD40-7A3F-4F8A-B5F2-1705D3161909Q52624211-6A28D7C5-3B87-4D10-9FAC-69D119961DC4Q52624216-DFAEF897-B3C1-44F5-A7C2-B6543EE22FF0Q54920929-FA4C7DC8-475F-4B34-8979-D34E995515BFQ55239741-D5F9CC9C-226A-45FA-9D38-FB0CC3AA4E08Q58562144-D040B9F8-40CA-4F2E-97B4-1469F944F264
P2860
Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Extended followup and risk fac ...... for localized prostate cancer.
@en
Extended followup and risk fac ...... for localized prostate cancer.
@nl
type
label
Extended followup and risk fac ...... for localized prostate cancer.
@en
Extended followup and risk fac ...... for localized prostate cancer.
@nl
prefLabel
Extended followup and risk fac ...... for localized prostate cancer.
@en
Extended followup and risk fac ...... for localized prostate cancer.
@nl
P2093
P1476
Extended followup and risk fac ...... for localized prostate cancer.
@en
P2093
Christopher J Welty
Janet E Cowan
Jeffry P Simko
June M Chan
Katsuto Shinohara
Kirsten L Greene
Matthew R Cooperberg
Maxwell V Meng
Nannette Perez
Peter R Carroll
P304
P356
10.1016/J.JURO.2014.09.094
P407
P50
P577
2014-09-28T00:00:00Z